PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions - Takeaways - MDSpire

PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions

  • By

  • Jeremy Kwe

  • Martin Baunacke

  • Katharina Boehm

  • Ivan Platzek

  • Christian Thomas

  • Angelika Borkowetz

  • February 16, 2024

  • 0 min

Share

  • 1

    Multiparametric MRI is essential for detecting clinically significant prostate cancer in patients with PI-RADS 3 lesions.

  • 2

    The study found that PI-RADS upgrading to 4 is the strongest predictor for clinically significant prostate cancer.

  • 3

    Follow-up biopsies revealed that 60% of patients with PI-RADS 3 lesions had clinically significant prostate cancer.

  • 4

    Systematic biopsies detected more clinically significant prostate cancer compared to targeted biopsies in patients with PI-RADS 3.

  • 5

    PSA-density values were analyzed but did not outperform PI-RADS upgrading in predicting clinically significant prostate cancer.

Original Source(s)

PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions

  • by Jeremy Kwe, Martin Baunacke, Katharina Boehm, Ivan Platzek, Christian Thomas, Angelika Borkowetz

  • February 16, 2024

Related Content

Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies

Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores